Reported Reactions

Adverse event reports that FDA received

  • Search
  • Watch list

Dysgeusia adverse event reports that record this term

Kind of term
MedDRA preferred term
Plain meaning
altered taste

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on . The data have the reports that FDA received through .

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on .

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 73,466 adverse event reports that record the MedDRA preferred term Dysgeusia. In plain words, the term means: altered taste. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 2,443 reports in the 12 months to June 2026 and 2,829 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 303 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 2,443 (0.2%) record this term. Reports for female patients were 61.3% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

Altered taste. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 48 drug pages with 250 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Drugs that the reports with the term Dysgeusia name as a suspect product, in order of name
DrugClassReports with this term
AfinitorKinase inhibitor393
Anticoagulant Sodium CitrateAnti-coagulant1,165
ByettaGLP-1 receptor agonist600
CabometyxKinase inhibitor725
CarboplatinPlatinum-based drug350
ChantixPartial cholinergic nicotinic agonist1,514
ClarithromycinMacrolide antimicrobial717
Cymbalta255
DexamethasoneCorticosteroid309
DocetaxelMicrotubule inhibitor306
EnbrelTumor necrosis factor blocker735
ErivedgeHedgehog pathway inhibitor669
EsbrietPyridone335
FluorouracilNucleoside metabolic inhibitor253
ForteoParathyroid hormone analog595
GabapentinAnti-epileptic agent306
GilenyaSphingosine 1-phosphate receptor modulator289
Humira927
IbranceKinase inhibitor577
Incivek484
Lunesta3,740
MetforminBiguanide263
MetronidazoleNitroimidazole antimicrobial394
MiraLAXOsmotic laxative253
NexiumProton pump inhibitor382
OmeprazoleProton pump inhibitor403
OxaliplatinPlatinum-based drug273
PaclitaxelMicrotubule inhibitor291
Paxlovid7,338
Peg-Intron264
PegasysInterferon alpha1,257
Pegintron304
PrednisoneCorticosteroid373
Rebetol433
RevlimidThalidomide analog1,279
RibavirinNucleoside analog antiviral1,094
RubracaPoly(ADP-Ribose) polymerase inhibitor562
SaphrisAtypical antipsychotic325
SutentKinase inhibitor1,635
SymbicortCorticosteroid319
Tecfidera286
Tiotropium bromideAnticholinergic329
Victrelis846
VotrientKinase inhibitor468
Vx-950339
Xiidra1,090
XtandiAndrogen receptor inhibitor525
XyremCentral nervous system depressant273

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 59 pharmacologic classes with 250 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Pharmacologic classes of the drugs that the reports with the term Dysgeusia name, in order of name
ClassReports with this term
Aminoglycoside antibacterial256
Aminoketone336
Aminosalicylate348
Androgen receptor inhibitor593
Angiotensin 2 receptor blocker746
Anti-coagulant1,172
Anti-epileptic agent599
Anticholinergic829
Aromatase inhibitor426
Atypical antipsychotic695
Benzodiazepine392
beta2-Adrenergic agonist300
Biguanide434
Calcitonin gene-related peptide receptor antagonist259
CD20-directed cytolytic antibody326
Central nervous system depressant304
Central nervous system stimulant345
Cholinergic nicotinic agonist644
Corticosteroid2,944
Factor Xa inhibitor286
Fluoroquinolone antibacterial286
Folate analog metabolic inhibitor390
GLP-1 receptor agonist1,824
Hedgehog pathway inhibitor757
HER2/neu receptor antagonist692
Histamine-1 receptor antagonist326
HMG-CoA reductase inhibitor840
Insulin analog365
Integrin receptor antagonist524
Interferon alpha1,332
Janus kinase inhibitor338
Kinase inhibitor6,426
l-Thyroxine378
Macrolide antimicrobial829
Microtubule inhibitor715
Nitroimidazole antimicrobial508
Nonsteroidal anti-inflammatory drug1,117
Nucleoside analog antiviral1,178
Nucleoside metabolic inhibitor865
Opioid agonist600
Osmotic laxative432
Parathyroid hormone analog612
Partial cholinergic nicotinic agonist1,535
PCSK9 inhibitor259
Platinum-based drug835
Poly(ADP-Ribose) polymerase inhibitor960
Programmed death Receptor-1 blocking antibody573
Prostacycline vasodilator348
Proton pump inhibitor1,646
Pyridone342
RANK ligand inhibitor277
Serotonin and norepinephrine reuptake inhibitor266
Serotonin reuptake inhibitor820
Sodium-Glucose cotransporter 2 inhibitor268
Sphingosine 1-phosphate receptor modulator300
Thalidomide analog1,565
Tumor necrosis factor blocker1,434
Vascular endothelial growth factor inhibitor418
Vitamin K antagonist300

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Dysgeusia, by month, five years to June 2026
01,0002,00020222023202420252026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Dysgeusia
AgeReportsShareShare as a bar
Under 2540.1%
2 to 113830.5%
12 to 172260.3%
18 to 448,65911.8%
45 to 6419,43926.5%
65 to 7410,81314.7%
75 and over6,6549.1%
Age not given27,23837.1%
Sex of the patient in the reports that record Dysgeusia
SexReportsShareShare as a bar
Female45,03161.3%
Male21,99329.9%
Unknown or not given6,4428.8%

Age and sex are as the report gives them. 79.7% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

The site checked these addresses on . The links open in a new tab.

Cite this page

Embed this card on your site

Copy this code into your page. The card shows the figures above with their source. A line under the card links to this page.

How embedding works. It is free. Keep the link in the card and the link line under it.

Reported Reactions. Dysgeusia: adverse event reports that record this term. https://reportedreactions.com/reaction/dysgeusia/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of . Reports received through .

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Dysgeusia mean in an adverse event report?

In plain words: altered taste. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.

Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on .